MK-2206, a potent oral allosteric AKT inhibitor that enhances the antitumour potency of chemotherapeutic agents (Ji et al. 2017), had no effect on normal peripheral blood mononuclear cells, but induced G1-phase arrest and apoptosis in leukemia cells (Lu et al. 2015), and induction of apoptosis by combined treatment of bufalin in multiple myeloma cells (Xiang et al. 2017). Here, AKT1 is linked to AL amyloidosis.